StreptInCor: A Candidate Vaccine Epitope against S. pyogenes Infections Induces Protection in Outbred Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Postol, Edilberto ^a   Alencar, Raquel ^a   Higa, Fabio T ^a   Freschi de Barros, Samar ^a   Demarchi, Lea M F ^a   Kalil, Jorge ^a   Guilherme, Luiza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CARDIAC MYOSIN; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; M PROTEIN; STREPTINCOR VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; BACTERIAL ADHESION; BACTERIAL VACCINES; BREEDING; CELL LINE; CELL PROLIFERATION; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; SPECIES SPECIFICITY; SPLEEN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

ANIMALIA; MUS; MUS MUSCULUS; STREPTOCOCCUS PYOGENES;

EID: 84876009986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060969     Document Type: Article

References (38)

1. Tart AH, Walker MJ, Musser JM, (2007) New understanding of the group A Streptococcus pathogenesis cycle. Trends Microbiol 15: 318-325.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M, (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5: 685-694.
3. Sociedade Brasileira de Cardiologia, (2009) [Brazilian guidelines for the diagnosis, treatment and prevention of rheumatic fever]. Arq Bras Cardiol 93(3Suppl 4): 3-18.
4. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S, (1995) Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics 96: 758-764.
5. Brook I, (2007) Overcoming penicillin failures in the treatment of Group A streptococcal pharyngo-tonsillitis. Int J Pediatr Otorhinolaryngol 71: 1501-1508.
6. Bisno AL, Rubin FA, Cleary PP, Dale JB, (2005) Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles-report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 41: 1150-1156.
7. Fischetti VA, (1991) Streptococcal M protein. Sci Am 264: 58-65.
8. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, et al. (2004) Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292: 709-715.
9. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, et al. (2005) Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41: 1114-1122.
10. Dale JB, Penfound TA, Chiang EY, Walton WJ, (2011) New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29: 8175-8178.
11. Bessen D, Fischetti VA, (1988) Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med. 167: 1945-1950.
12. Kotloff KL, Wasserman SS, Jones KF, Livio S, Hruby DE, et al. (2005) Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun 73: 2360-2366.
13. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, et al. (2005) Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 192: 1450-1455.
14. Olive C, Hsien K, Horváth A, Clair T, Yarwood P, et al. (2005) Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 23: 2298-2303.
15. Vohra H, Dey N, Gupta S, Sharma AK, Kumar R, et al. (2005) M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 156: 575-582.
16. Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, et al. (2007) Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 25: 1789-1797.
17. Cunningham MW, (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13: 470-511.
18. Guilherme L, Kalil J, (2010) Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 30: 17-23.
19. Guilherme L, Köhler KF, Postol E, Kalil J, (2011) Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol 4: 13-21.
20. Guilherme L, Faé KC, Higa F, Chaves L, Oshiro SE, et al. (2006) Towards a vaccine against rheumatic fever. Clin Dev Immunol 13: 125-132.
21. Guilherme L, Postol E, Freschi de Barros S, Higa F, Alencar R, et al. (2009) A vaccine against S. pyogenes: design and experimental immune response. Methods 49: 316-321.
22. Guilherme L, Alba MP, Ferreira FM, Oshiro SE, Higa F, et al. (2011) Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem 286: 6989-6998.
23. Guerino MT, Postol E, Demarchi LMF, Martins CO, Mundel LR, et al. (2011) HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine 29: 8250-8256.
24. Pfoh E, Wessels MR, Goldmann D, Lee GM, (2008) Burden and economic cost of group A streptococcal pharyngitis. Pediatrics 121: 229-234.
25. Danchin MH, Rogers S, Kelpie L, Selvaraj G, Curtis N, et al. (2007) Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics 120: 950-957.
26. Jaine R, Baker M, Venugopal K, (2008) Epidemiology of acute rheumatic fever in New Zealand 1996-2005. J Paediatr Child Health 44: 564-571.
27. Bronze MS, Dale JB, (2010) Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections. Am J Med Sci 340: 218-225.
28. Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, et al. (1996) Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci USA 96: 10338-10343.
29. Lindblad EB, (2004) Aluminium compounds for use in vaccines. Immunol Cell Biol 82: 497-505.
30. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC, (2004) Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304: 1808-1810.
31. Guilherme L, Köhler KF, Kalil J, (2011) Rheumatic heart disease: mediation by complex immune events. Adv Clin Chem 53: 31-50.
32. Quinn A, Ward K, Fischetti VA, Hemric M, Cunningham MW, (1998) Immunological relationship between the class I epitope of streptococcal M protein and myosin. Infect Immun 66: 4418-4424.
33. Cunningham MW, (2001) Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis. Am J Pathol 159: 5-12.
34. Cunningham MW, (2004) T cell mimicry in inflammatory heart disease. Mol Immunol 40: 1121-1127.
35. Faé KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, et al. (2006) Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 176: 5662-5670.
36. Smeesters PR, Vergison A, Campos D, de Aguiar E, Miendje Deyi VY, et al. (2006) Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 1: e10.
37. Smeesters PR, Mardulyn P, Vergison A, Leplae R, Van Melderen L, (2008) Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 26: 5835-5842.
38. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, et al. (2007) The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 45: 853-862.